Pfizer and Flynn Pharma fined €101 million for charging the UK health service excessive prices for Phenytoin sodium capsules, an anti-epilepsy drug

by Dechert LLP

Dechert LLP

The UK Competition and Markets Authority (“CMA”) recently published its infringement decision of 7 December 2016 that imposed a fine on Pfizer1 and Flynn Pharma2 (“Flynn”) for abusing their respective dominant positions by charging excessive and unfair prices for phenytoin sodium capsules (“Phenytoin”).

In Europe, Aspen Pharmacare was recently fined by the Italian Competition Authority for similar practices, and is currently under investigation by the European Commission (“Commission”) for having allegedly implemented excessive prices in several EU Member states on five cancer drugs.

This sends a very clear message to pharmaceutical companies: competition authorities in the EU are willing to investigate drugs’ price levels in spite of national price regulations set by health authorities.

Summary of CMA’s findings

In 2012, Pfizer sold its UK Market Authorizations (“MAs”) for its Phenytoin brand Epanutin to Flynn, a pharmaceutical company specializing in the acquisition of so-called “end of life” products. Pfizer received a nominal fee of £13 and continued to manufacture its Phenytoin capsules, which it supplied exclusively to Flynn at prices that were up to 1,600% higher than what it charged customers prior to the transfer. At that time, the prices of Epanutin were regulated in the UK as part of Pfizer’s portfolio of branded drugs under the National Health Service (“NHS”) Pharmaceutical Price Regulation Scheme (“PPRS”).4

Flynn subsequently requested and obtained from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) the approval to de-brand Epanutin. Consequently, the drug was withdrawn from the PPRS which allowed Flynn to significantly increase its prices.

Two product characteristics of Phenytoin severely limit customers’ ability to switch between different brands, namely its narrow therapeutic index and non-linear pharmacokinetics. These features mean that even small changes to the dose delivered to the circulation can give rise to a disproportionate change in drug’s level in the body. This may lead to therapeutic failure and toxic side effects, including the loss of seizure control. As a result, clinical guidance issued by the National Institute for Health and Care Excellence (“NICE”) and the Medicines and Healthcare Products Regulatory Agency (“MHRA”) recommends that patients who are stabilised on a particular manufacturer’s Phenytoin should not be switched to another manufacturer’s product.

The difficulties in switching to another brand meant that Flynn was able to increase the price it charged UK customers by up to 2,600% (while the price of Epanutin remained unchanged in other EU countries). This led to an annual increase of NHS’s expenditure on this product totalling €54 million.

The CMA opened a formal investigation in May 2013 following a complaint by the UK Department of Health (“DH”) that was lodged in September 2012.

CMA’s characterization of the excessive prices

The CMA’s infringement decision covers the excessive prices that Flynn was charged by Pfizer, and the excessive prices that Flynn charged its customers. It found that Pfizer and Flynn’s pricing practices constituted an abuse of their dominant position on the market for the manufacture of Phenytoin distributed in the UK and the market for the distribution of Phenytoin in the UK, respectively.

The CMA applied the cumulative two-stage test set forth by the European Court of Justice in its United Brands judgment to assess whether a price is unfairly high. The test involves assessing whether (i) the difference between the costs actually incurred and the price actually charged is excessive; and if so, (ii) whether a price has been imposed which is unfair either in itself or when compared to competing products.

In order to determine whether the difference between the product costs and the prices charged by Pfizer and Flynn were excessive, the CMA used the following benchmarks: (i) the rate of return of both companies on products other than Epanutin (between 5% and 19%); (ii) the target rate of return set by the PPRS (6%); and (iii) the rate of return of other pharmaceutical companies selling off-patent drugs (between 16.4% and 25.1%). The CMA’s assessment was also guided by the Commission’s infringement decision in Deutsche Post in which the imposition of a price 25% above the costs reasonably attributable to the product (i.e., the excess) was found to be excessive; and the judgment of the UK Competition Appeal Tribunal (“CAT”) in Albion Water II where an excess of at least 46.8% was considered excessive.

Based on the above factors, the CMA concluded that the prices charged by Pfizer to Flynn, and the prices charged by Flynn to wholesalers and pharmacists were excessive. In Pfizer’s case, the excess, including a reasonable rate of return, ranged between 29% (for 25 mg capsules) and 690% (for 300 mg capsules). The excess in Flynn’s prices, including a reasonable rate of return, varied between 31% (for 100 mg capsules) and 133% (for 25 mg capsules).

The CMA found that the unfairness limb of the United Brands test was satisfied since the price increases were not justified by any significant change in the costs of production. In particular, notwithstanding the fact that all of Pfizer’s European supplies of Epanutin are manufactured at its plant in Germany, prices in other EU Member States were considerably lower than those charged to UK customers. On this basis, the CMA rejected Pfizer’s argument that Phenytoin was produced at a loss. Moreover, the price increases were not justified by any significant changes in the costs of supply since the distribution of Phenytoin into the UK was undertaken by a third party (as opposed to Flynn) or by any new product-specific risks or innovation costs.

As part of its assessment, the CMA also relied on the parties’ contemporaneous internal documents as evidence. Those documents revealed that both parties pursued a common aim during negotiations for the transfer of Pfizer’s UK Phenytoin MAs, namely mitigating the risk of Pfizer suffering any reputational damage due to the price increases by deflecting negative customer reactions from Pfizer to Flynn. According to the CMA, Pfizer and Flynn were aware that the price increases would necessarily have an adverse effect on both (i) the NHS’s budget, and (ii) Epanutin users, since the NHS is required to procure the product for a category of patients under the UK health agencies’ clinical guidance.

Fines and remedies

The CMA fined Pfizer and Flynn approximately €95 million and €6 million, respectively. Due to the personal involvement of Flynn’s directors and senior management, in particular its CEO and Director, in the planning and implementation of the infringement, the CMA increased Flynn’s fine by an amount which was not disclosed in the public version of the decision.

In addition to the fines, the CMA’s directions ordered both companies to reduce their prices within 30 days. Although the directions stipulated that the Parties should be guided by the CMA’s decision when setting their revised prices, the CMA did not go as far as setting a price noting that it is not a price regulator and that the parties are responsible for assessing their own compliance with competition law. The companies were also ordered to notify the CMA of any price changes for a period of 10 years following the issue of the directions.

Both companies are currently appealing the CMA’s decision to the CAT. Flynn also made an unsuccessful application for interim relief to prevent the CMA’s directions from taking effect pending the outcome of its appeal arguing that it stood to suffer serious and irreparable harm including financial losses, a potentially permanent effect on market prices and changes to the organization of its business. Although the CAT found that Flynn would suffer significant irrecoverable financial harm, it concluded that this was outweighed by the potential harm to patients and the NHS.

If CAT upholds the CMA’s decision, several potential claimants, and in particular the NHS, may bring actions for damages against Pfizer and Flynn. The main hearing is scheduled to commence on 30 October, 2017.

Key Takeaways:

  • Due to political pressure, competition authorities seem to be willing to aggressively pursue excessive pricing cases in the pharmaceutical sector, a previously underused category of infringement; and
  • By referring to notions such as “excessive” or “reasonable” prices to determine whether pricing behaviour constitutes an abuse of dominance, the competition authorities have left themselves a significant margin of discretion.


1) In Pfizer’s statement issued on 7 December 2016, Pfizer indicated that “[i]t believes the CMA’s findings are wrong in fact and law and will be appealing all aspects of the Decision” (emphasis added). 

2) In Flynn's statement issued after the publication of the CMA’s infringement decision, Flynn indicated that “Flynn will appeal to overturn the CMA’s findings in the courts. We are confident the CMA’s findings will be overturned” (emphasis added).

3) Competition Appeal Tribunal, 19 January 2017, Flynn Pharma Limited vs CMA (interim relief judgement), § 14.

4) PPRS is a voluntary agreement between the UK Government and the pharmaceutical industry, whose. Its dual aim is to regulate the price of branded products while allowing pharmaceutical companies to make a reasonable profit.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.